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background:  Endovascular left atrial appendage (LAA) closure is increasingly being performed in patients with atrial fibrillation (AF) who 
are ineligible for oral anticoagulation (OAC), or as an alternative to OAC. In particular, patients with previous intracranial haemorrhage 
or intraocular bleed may have dire consequences with recurrent bleeding if OAC is initiated/re-initiated. We evaluated the safety and 
outcomes of patients with intracranial and intraocular bleed who underwent LAA closure.
Methods:  We report our consecutive series of non-valvular AF patients with prior intracranial or intraocular bleed who underwent LAA 
closure with the Amplatzer Cardiac Plug (ACP), Amulet, or Watchman devices at Vancouver General Hospital. Indications for LAA closure 
was CHADS2 score ≥1 and CHADS-VASc ≥2, and contraindications to OAC. Procedures were done under general anaesthesia and 
transesophageal echocardiographic guidance. Baseline demographics, procedural events, and clinical outcomes were reported. Patients 
were followed post-procedure prospectively at 1-3mth, 1yr, and annually thereafter. Dual antiplatelet therapy (DAPT) was recommended for 
1-3mth post-LAA closure.
results:  Twenty-three patients with prior intracranial (n=21) or intraocular bleed (n=2) underwent LAA closure (11 ACP, 5 Amulet and 
7 Watchman). Mean age was 77±7yr, 57% were male with a mean CHADS2 score 3.3±1.4 and CHADS-VASc 5.0±1.6. Seven patients 
had paroxysmal AF. Post-procedure, 11 patients received DAPT for 1mth, 9 received DAPT for 3mth, while 2 had aspirin alone and 1 had 
clopidogrel alone post-procedure. No procedure-related complications occurred. There was 1 device embolization (ACP) found day-1 post-
procedure that was successfully retrieved percutaneously uneventfully. Mean follow-up was 13.3±14mth. One patient was diagnosed with 
a transient ischemic attack 20.6mth post procedure. No ischemic stroke, haemorrhagic stroke, systemic embolism, major bleeding or death 
occurred during follow-up.
Conclusion:  LAA closure is safe and effective in patients with prior intracranial or intraocular bleeding. DAPT for 1-3mth post-LAA closure 
in this patient cohort appeared feasible.
